Abstract
Currently available chemotherapy for the treatment of pulmonary tuberculosis (TB) is far from ideal, requiring multiple anti-tuberculous drugs to be taken in combination for extended time periods. This long duration of therapy, coupled with the side effects of current regimens, often results in poor patient adherence, treatment failure and the associated emergence of drug resistance with major financial implications. Thus, the development of novel, shorter treatment regimens is an urgent objective of anti-tuberculous drug discovery. Immunotherapy is an area that merits more consideration than it has previously received, not least, as it could potentially avoid the problem of pathogen resistance. However, this must be undertaken with caution, as at least part of the disease pathology is a consequence of the host immune response. Thus, the protective, and not the harmful, aspects of immunity must be stimulated. Various attempts at utilizing immunotherapy as an adjunct to chemotherapy are reviewed with particular emphasis on the evidence from human studies, including the modulation of cytokine levels, administration of environmental mycobacteria and antibody therapy, in order to modulate or enhance the host immune response to Mycobacterium tuberculosis.
Keywords: Protective immunity, cytokines, corticosteroids, therapeutic antibody, gammaglobulin, thalidomide, therapeutic vaccines, drug resistant, MDR, XDR
Current Molecular Medicine
Title: Current Strategies in TB Immunotherapy
Volume: 7 Issue: 4
Author(s): Eleanor Roy, Douglas B. Lowrie and Stephen R. Jolles
Affiliation:
Keywords: Protective immunity, cytokines, corticosteroids, therapeutic antibody, gammaglobulin, thalidomide, therapeutic vaccines, drug resistant, MDR, XDR
Abstract: Currently available chemotherapy for the treatment of pulmonary tuberculosis (TB) is far from ideal, requiring multiple anti-tuberculous drugs to be taken in combination for extended time periods. This long duration of therapy, coupled with the side effects of current regimens, often results in poor patient adherence, treatment failure and the associated emergence of drug resistance with major financial implications. Thus, the development of novel, shorter treatment regimens is an urgent objective of anti-tuberculous drug discovery. Immunotherapy is an area that merits more consideration than it has previously received, not least, as it could potentially avoid the problem of pathogen resistance. However, this must be undertaken with caution, as at least part of the disease pathology is a consequence of the host immune response. Thus, the protective, and not the harmful, aspects of immunity must be stimulated. Various attempts at utilizing immunotherapy as an adjunct to chemotherapy are reviewed with particular emphasis on the evidence from human studies, including the modulation of cytokine levels, administration of environmental mycobacteria and antibody therapy, in order to modulate or enhance the host immune response to Mycobacterium tuberculosis.
Export Options
About this article
Cite this article as:
Roy Eleanor, Lowrie B. Douglas and Jolles R. Stephen, Current Strategies in TB Immunotherapy, Current Molecular Medicine 2007; 7 (4) . https://dx.doi.org/10.2174/156652407780831557
DOI https://dx.doi.org/10.2174/156652407780831557 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis of a Tetrasaccharide Present in Motif B of the Mycobacterium tuberculosis Cell Wall
Letters in Organic Chemistry Integrating Virtual Screening and Combinatorial Chemistry for Accelerated Drug Discovery
Combinatorial Chemistry & High Throughput Screening Graphical Abstracts:
Letters in Drug Design & Discovery Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Novel Pthalazinyl Derivatives: Synthesis, Antimycobacterial Activities, and Inhibition of Mycobacterium Tuberculosis Isocitrate Lyase Enzyme
Medicinal Chemistry How do Mutations of Mycobacterium Genes Cause Drug Resistance in Tuberculosis?
Current Pharmaceutical Biotechnology Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Antimycobacterial Evaluation of Pyrazinoic Acid Reversible Derivatives
Current Pharmaceutical Design Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CRISPeering: Bioengineering the Host Cells through CRISPRCas9 Genome Editing System as the Next-generation of Cell Factories
Recent Patents on Biotechnology Iminosugars and Relatives as Antiviral and Potential Anti-infective Agents
Current Topics in Medicinal Chemistry Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review
Current Topics in Medicinal Chemistry A Review of Biological Applications of Transition Metal Complexes Incorporating N-acylhydrazones
Mini-Reviews in Organic Chemistry Tuberculosis Vaccines: Hopes and Hurdles
Infectious Disorders - Drug Targets Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Leishmaniasis: Prevention, Parasite Detection and Treatment
Current Medicinal Chemistry Pharmacogenetics of Cytochromes P450 in Tropical Medicine
Current Drug Targets Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Patent Selections
Recent Patents on Anti-Infective Drug Discovery Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting
Current Pharmaceutical Design